Highlights the rare but serious postmarketing safety risks of isolated thrombocytopenia and thrombotic thrombocytopenic purpura associated with prasugrel therapy.
Answers are grounded in this paper and cite their sources.
No results reported; leaves open any role for intravenous low-molecular-weight heparin.
gained popularity since its approval by the Food and Drug Administration (FDA) in 2009. Prasugrel is more effective because it requires only a single-step bioactivation, leading to faster activity, less varied action in patients, and more potent platelet suppression. However, it has been reported to have major adverse effects such as hypertension, hyperlipidemia, backache, headache, and epistaxis. Uncommon adverse effects seen in postmarketing surveillance and/or case reports include abnormal hepatic function tests, anaphylaxis, angioedema, hypersensitivity reaction, thrombocytopenia, and thrombotic thrombocytopenic purpura. In a randomized, doubleblind, comparative study [(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with PrasugrelThrombolysis in Myocardial Infarction (TRITONTIMI 38)], treatment with oral prasugrel was more effective compared with clopidogrel in reducing rates of ischemic cardiovascular events including myocardial infarction and stent thrombosis, however, there was an increased risk of bleeding, including fatal bleeding, compared with clopidogrel. The adverse events reported included severe thrombocytopenia in 17 patients in the prasugrel group (0.3%) and 18 patients in the clopidogrel group.1 Thrombocytopenia and thrombotic thromboyctopenic purpura (TTP) due to prasugrel have been reported in postmarketing surveillance.1 Estimation of exact frequency of such reactions is arduous because these reactions are voluntarily reported. Jacob et al studied 20 years of information on clinical, epidemiologic, and laboratory findings for thienopyridine-associated TTP. Fourteen cases of prasugrel-associated TTP were reported in 2009 and 2010. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13), also known as von Willebrand factor cleaving protease (VWFCP) is a large protein involved in blood clotting. ADAMTS 13 deficiency is implicated in ticlopidineassociated cases, ADAMTS-13 independence is implicated in clopidogrel-associated TTP cases; however, ADAMTS-13 information for prasugrel-associated TTP is unknown.2 Although isolated thrombocytopenia due to prasugrel has been identified in its postmarketing data, formal reporting has not been previously published.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2019) conducted a review in Prasugrel-associated thrombocytopenia and thrombotic thrombocytopenic purpura (TTP). Prasugrel vs. Clopidogrel was evaluated on Severe thrombocytopenia and thrombotic thrombocytopenic purpura (TTP).
Synapse has enriched 10 related papers. Consider them for comparative context: